X

Trial Profile

Phase I Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Japanese Patients with Previously Treated, Unresectable/Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lurbinectedin (Primary)
Indications Advanced breast cancer; Endometrial cancer; Oropharyngeal cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions
Sponsors IQVIA; PharmaMar

Most Recent Events

14 Mar 2022 Planned End Date changed from 1 Sep 2019 to 31 May 2020.
14 Mar 2022 Status changed from active, no longer recruiting to completed.
21 Sep 2020 Results (n=11) presented at the 45th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com